Michael O'Dwyer to Treatment Outcome
This is a "connection" page, showing publications Michael O'Dwyer has written about Treatment Outcome.
Connection Strength
0.160
-
Epigenetic regulatory pathways involving microRNAs may modulate the host immune response following major trauma. J Trauma Acute Care Surg. 2015 Nov; 79(5):766-72.
Score: 0.081
-
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025 Apr; 39(4):942-950.
Score: 0.039
-
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL. Leuk Lymphoma. 2018 06; 59(6):1338-1347.
Score: 0.023
-
A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. Br J Haematol. 2013 Oct; 163(1):118-22.
Score: 0.017